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Effects of linoleic acid on generalized convulsive and nonconvulsive epileptic seizures
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Background/aim: To comparatively investigate the effects of linoleic acid on convulsive and nonconvulsive epileptic seizures.
Materials and methods: Rats were divided into 3 groups: convulsive epileptic rats receiving only pentylentetrazole (PTZ) injections
(group 1), convulsive epileptic rats receiving PTZ and linoleic acid (group 2), and Wistar Albino Glaxo rats from Rijswijk with genetic
absence epilepsy receiving linoleic acid (group 3). The duration and severity of convulsive activity were determined in groups in which
convulsive seizures were induced by PTZ. In group 3, intravenous linoleic acid was administered after 1-h baseline electroencephalography
(EEG) recordings. The EEG recordings were analyzed.
Results: When groups 1 and 2 were compared, the delay in onset of minor seizures and the decrease in the number of rats developing
major seizures were found statistically significant. When the mean spike-wave discharge number and duration values for the rats in
group 3 were compared to baseline values, a statistically significant increase was found in the 1st and 6th hours and there was no
significant difference in the 24th hour.
Conclusion: While our study shows that linoleic acid may be effective in the treatment of generalized convulsive epilepsy along
with conventional antiepileptic drugs used in epilepsy treatment, it reports that linoleic acid is not appropriate in the treatment of
nonconvulsive epilepsies.
Key words: Linoleic acid, epilepsy, pentylentetrazole

1. Introduction
Epileptic seizure is the generation of abnormal, excessive,
and hypersynchronized activity in the cortical and
subcortical neurons due to several factors in the central
nervous system. The condition where seizures show a
tendency to relapse and become chronic is called epilepsy.
Epilepsy, among the common neurological diseases of
the brain, affects approximately 1% of the population
(1–4). In addition, recurrent seizures are a significant
cause of childhood morbidity (5). Generalized seizures
can be subdivided into 2 groups: generalized tonic-clonic
seizures and generalized absence seizures (6). The focal or
generalized convulsive seizures observed in epilepsy are
caused by an increase in the excitability in a specific region
of brain cortex or subcortical structures or throughout
the cortex. The reflections in electroencephalography
(EEG) of the excitability increase occurring in the cortex
during generalized seizures are EEG segments in the form
of spike and spike-wave complexes. The excitability level
in the brain neurons depends on the balance between
* Correspondence: drfatihekici@hotmail.com

excitatory and inhibitory effects. The excitability increase
is theoretically dependent on the increase of excitatory
effectiveness or the decrease in inhibitory effectiveness
(i.e. disinhibition). The main event in the regulation of
excitability at the neuronal level is the alteration of the
permeability to Na+, Ca++, K+, and Cl- ions. The excitation
at the neuronal level is dependent on the increase in
permeability of cell membranes to Na+ and in some
neurons to Ca++. The inhibition, however, is caused by an
increase in the Cl- or K+ permeability. Convulsive seizures
are caused by the dysfunction of a large cell population,
which initiates local paroxysmal discharges, as a result of an
over-release of glutamate and aspartate as well as increased
N-methyl-D-aspartic acid receptor activity. The discharges
propagating from the sites of origin to the other regions
via abnormal dendritic meshwork cause the generation
of focal seizures by firing the neurons without inhibitory
mechanisms. The progression of discharge propagation
leads to generalized seizures. The excitatory discharges
deactivate the inhibitory mechanisms, which are under
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the control of gamma-aminobutyric acid (GABA)-ergic
neurons (2,3,7).
Absence epilepsy, which is also classically known as
petit mal seizure, is a form of nonconvulsive generalized
epilepsy and its pathology is different from convulsive
seizures. In the classical EEG pattern there are spikewave discharges (SWDs) accompanying the seizure
(2,8). There are many studies showing that GABAA and
GABAB receptors are involved in the generation of SWDs
(9,10). An increase in GABAergic activity can induce the
generation of SWDs by increasing the intensity of the
absence seizures in humans and animal models through
inhibition and synchronization of neuronal firing. It was
also shown that neurotransmitters other than GABA
and ion channels could also be effective in the control of
intrinsic oscillatory mechanisms (11).
While many new antiepileptic agents have been
introduced in recent years, no significant changes
have been observed in the distribution of patients not
responding to pharmacotherapy. Therefore, there is a need
for new approaches in epilepsy treatment.
Essential fatty acids are required for the fluidity of the
membrane structure and the synthesis of eicosanoids.
The 2 fatty acids essential for humans are linoleic acid,
the precursor of prostaglandins, and linolenic acid (12).
Recent studies have found that polyunsaturated fatty acids
(PUFAs) are useful in epileptic seizures, brain ischemia,
depression, and several coronary diseases. It is believed that
PUFAs exert their corrective actions on neuronal damage
by affecting glutamate receptors, glutamate transporters,
and ion channels in brain. In addition, the ability of PUFAs
to readily pass through the blood-brain barrier enhances
their neuroprotective effects (13–15). It has been shown
that dietary lipids not only influence the biophysical state
of cell membranes but, via direct and indirect routes,
they also act on multiple pathways including signaling
and gene and protein activities (16).
The effect of PUFAs on epileptic seizures was
investigated in several studies performed by establishing
in vitro and in vivo models with controversial results (17).
Furthermore, their effects on absence epilepsy have not
been completely understood. Therefore, in our study the
effects of PUFAs on 2 types of generalized epilepsy were
investigated. Pentylentetrazole (PTZ) was used to test the
effects of PUFAs on generalized tonic-clonic epilepsy and
Wistar Albino Glaxo rats from Rijswijk (WAG/Rij) were
used to test the effects of PUFAs on absence epilepsy.
2. Materials and methods
2.1. Animals
In our study, Wistar Albino rats (in the convulsive group)
and 9 month old WAG/Rij (in the nonconvulsive group)
of 200–300 g in weight, raised in the Kocaeli University
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(KOU) School of Medicine Experimental Medicine
Research Laboratory, were used. All animals had free
access to food and water. During the experiments attention
was paid to protecting animal rights and the study was
initiated after the approval of the KOU Ethics Committee.
Two experimental groups were formed: the convulsive
seizure group of Wistar rats with PTZ administration
and the nonconvulsive (absence) seizure group of WAG/
Rij strain rats, genetically predisposed to absence epilepsy
(18).
2.1.1. Convulsive epilepsy group (n = 7)
Epileptic seizure activity was assessed for 30 min following
intraperitoneal (i.p.) injections of 60 mg/kg PTZ using
the scale described by Mares et al. (19). The experimental
group (n = 7) that was administered PTZ (i.p.) 30 min
after intravenous (i.v.) administration of 100 nmol/kg
linoleic acid was also assessed with the same method and
statistically compared.
2.1.2. Spontaneous nonconvulsive absence epilepsy
group (n = 7)
EEG 1-h baseline recordings were obtained from the
WAG/Rij rats, which were implanted with epidural tripolar
EEG electrodes under anesthesia (20). In the rats that were
administered 100 mmol/kg of i.v. linoleic acid, the mean
number and duration (s) values of SWDs were compared
with the baseline values.
2.2. EEG recording electrode implantation
In the epilepsy groups, the rats were chronically implanted
with tripolar electrodes (Plastic Products Company MS
333/2A) in the skull for EEG evaluation. For this purpose,
rats were anesthetized with ketamine (100 mg/kg, i.p.) and
chlorpromazine (1 mg/kg, i.p.), placed in a stereotaxic
device (Stoelting Model 15600), and held in place by their
ears and teeth. The scalp was opened and the lambda
and bregma were exposed. The bregma was used as a
reference point. The recording electrodes were implanted
at the frontal region coordinates of 2 mm anterior and 3.5
mm lateral and the parietal region coordinates of 6 mm
posterior and 4 mm lateral, and the reference electrode
was implanted in the cortex above the cerebellum and
held in place with the help of dental acrylic. After this
procedure the animals were allowed to rest for 1 week. The
EEG recordings were obtained using the EEG100B Biopac
System.
2.3. Epileptic seizure activity assessment
2.3.1. Evaluation of convulsive seizures
Epileptic seizure activity was evaluated for 30 min following
i.p. injections of 60 mg/kg PTZ with respect to seizure
onset time, seizure severity, and total seizure duration. The
scale described by Mares et al. was used for the evaluation
of generalized seizure severity (19). According to this
scale: 0 = no behavioral changes, 0.5 = atypical behavior, 1
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= isolated myoclonic jerks, 2 = atypical minimal seizures,
3 = minimal seizures (with preserved righting reflex), 4 =
major seizures (without tonic phase), and 5 = complete
generalized tonic-clonic seizures (CGTCs).
Abnormal behavior changes, isolated myoclonic jerks,
and clonic seizures accompanying the clonus of facial and
forelimb were considered as minimal PTZ seizures. The
subsequent onset of loss of righting reflex with extension
of head, neck, and tail was considered as major PTZ seizure
without tonic phase and the prolonged clonuses following
tonic flexion or extension as complete major seizure. The
seizure onset time was determined by measuring the
time to occurrence of the first myoclonic jerk following
the PTZ administration. The generalized tonic-clonic
seizure latency was determined by recording the time to
occurrence of the major seizure. Seizure duration was
determined by measuring the major seizure duration and
all time values were expressed in seconds (19).
2.3.2. The evaluation of absence seizures
The 1-h baseline EEG recordings and the EEG recordings
obtained during the 1st, 6th, and 24th hours after the
linoleic acid administration were analyzed and the number
and duration (s) of SWDs were assessed.
2.4. Statistical evaluation
The data were expressed as mean ± standard error (SE).
In the convulsive epilepsy groups, the delay in the time
to onset of minor seizure was evaluated using the Mann–
Whitney U test and the decrease in the number of rats
developing major seizures was assessed with the chi-square
test. The changes in major seizure latency and total major
seizure duration were not included in the assessment due
to the low number of rats experiencing seizures. In the
absence epilepsy group, the comparisons among 1st, 6th,
and 24th hour values and baseline values, with respect
to the mean number and duration values of SWDs, were
performed using the Friedman test and subsequently with
the Bonferroni correction Wilcoxon signed ranks test. In
all tests, P < 0. 05 was accepted as statistically significant.
PTZ

3.1. Convulsive epilepsy group (n = 7)
In the PTZ-administered group, generalized tonic-clonic
seizure activity developed in all rats. In this group, the mean
time to onset of minor seizure was 91.4 ± 59 s, the major
seizure latency was 237.8 ± 104 s, and the major seizure
duration was 82.7 ± 18.9 s. In the experimental group,
which was administered PTZ 30 min after 100 nmol/kg of
linoleic acid administration, no major seizures developed
in 5 of the 7 rats and very short-duration CGTC developed
in only 2 rats. The mean time to onset of minor seizure
was 133.5 ± 5.6 s, the major seizure latency was 430 ± 35
s, and the major seizure duration was 7.5 ± 2. 5 s. When
these values were compared to the PTZ group, the delay in
the time to onset of minor seizure and the decrease in the
number of rats experiencing major seizures were found
to be statistically significant (P < 0. 05) (Figures 1a and
1b). The changes in major seizure latency and total major
seizure duration were not included in the assessment due
to the low number of rats experiencing seizures.
3.2. Nonconvulsive absence epilepsy group (n = 7)
Baseline activities of WAG/Rij rats were recorded before
the administration of linoleic acid (Figure 2a). In the 1-h
baseline (0900–1000 hours) EEG recordings, the mean
total SWD number and duration values were 16.5 ± 0.9
and 126.2 ± 18.3 s, respectively. In the experimental group
(Figure 2b), the mean SWD number and duration values in
the EEG recordings following linoleic acid administration
were 33.4 ± 3.5 and 253 ± 28.5 s in the 1st hour, 25.1 ± 3
and 202 ± 36.1 s in the 6th hour, and 16.8 ± 0.8 and 112.1 ±
22.1 s in the 24th hour (Figures 3a and 3b). In view of these
results, when compared to the baseline values, the mean
SWD number and duration values showed a statistically
significant increase in the 1st and 6th hours (P < 0. 05), but
no significant difference was observed in the 24th hour (P
> 0. 05).
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Figure 1a. The effects of linoleic acid on the time to onset of
minor seizures (*: P < 0. 05).
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Figure 1b. The development of CGTC in the convulsive epilepsy
group (*: P < 0. 05).
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Figure 2a. Epileptic activity of WAG/Rij rat group receiving
linoleic acid.
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Figure 2b. Epileptic activity of convulsive epileptic rat group
receiving PTZ and linoleic acid.
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Figure 3a. The increases in the numbers of SWDs between the
linoleic acid injection and the 1st and 6th hours were found
statistically significant (*: P < 0. 05).

Figure 3b. The increases in the durations of SWDs between the
linoleic acid injection and the 1st and 6th hours were found
statistically significant (*: P < 0. 05).

4. Discussion
4.1. In terms of convulsive epilepsy
The use of linoleic acid significantly prevented major seizure
development, delayed the onset of seizures, and decreased
the major seizure duration. These results are consistent
with the results of the limited number of studies on the
use of linoleic acid in convulsive epilepsies and the known
mechanisms of the effect of linoleic acid. The effect of
PUFAs on epileptic seizures was previously demonstrated
in some studies conducted by establishing in vitro and in
vivo models. In the in vitro model, seizure-like activity was
generated using glutamatergic neurons and linoleic acid
was shown to block the glutamatergic transmission. In the
in vivo model, in rats in which temporal lobe epilepsy was
induced by kainic acid, linoleic acid administration was
found to prevent epileptiform activity and also decrease
the hippocampal damage that occurs during seizures (13).
Moreover, in a study where various PUFAs were given to rats
in which a cortical stimulation model was established, it was

found that PUFAs had an anticonvulsant effect and that this
effect lasted for 6 h and had completely disappeared by the
following day (21). In the studies mentioned above and in
our study, it was shown that PUFAs had an anticonvulsant
effect and this effect lasted for 6 h. In particular, in a
very recent study conducted in rats with the same PTZ
model used in our study, the combined use of linoleic
and α-linoleic acid was found to increase the resistance
to PTZ seizures (17). With respect to convulsive epilepsy,
our study appears to be consistent with the limited number
of previous animal studies. PUFAs are thought to exert
their neuronal excitability-decreasing effect by inhibiting
glutamatergic synaptic transmission by partially inhibiting
the voltage-dependent Na+ and Ca++ channels as well as
by pre- and postsynaptically activating the 2 P-domain
channels (TREK-1, TREK-2, TRAAK), which is a recently
cloned K+ channel. In addition, it can be said that the ability
of PUFAs to pass through the blood–brain barrier easily
enhances their neuroprotective effects (13–15,17).
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4.2. In terms of nonconvulsive epilepsy (absence)
The results we obtained from our study show that
linoleic acid increased the number and duration of the
absence seizures that developed in the WAG/Rij rats. To
date, there are not enough literature data obtained from
the use of PUFAs in absence epilepsy that we can use to
compare with these results. In studies on the modulation
of Ca2+ channels in absence epilepsy, it was found that
the T-type channel blockage decreased the SWDs, while
the L-type channel blockage increased the SWDs (9). The
findings that the Ca2+ channels inhibited by PUFAs are
particularly L-type channels show that the inhibition of
L-type Ca2+ channels may be an important factor in the
development of the SWD-increasing effect of linoleic
acid. The Na+ channel-blocking effect of PUFAs results in
membrane stabilization and has an inhibitory effect. The
opening of K+ channels, however, is an event that causes
hyperpolarization by increasing K+ efflux. All of these
mechanisms may decrease the neuronal excitability and

aggravate the absence seizures, contrary to convulsive
seizures, by shifting the neurotransmitter balance towards
the inhibitory side (21).
In conclusion, the data we obtained show that linoleic
acid may be effective in the treatment of generalized
convulsive epilepsy. We believe that an increase in the
number of studies on this subject and the introduction of
these agents as combination treatment choices will open
new horizons in epilepsy treatment. However, according to
our results, the use of linoleic acid in absence epilepsy does
not appear to be appropriate. Our study also demonstrates
the pharmacological differentiation in convulsive and
nonconvulsive epilepsies. In the experimental and clinical
studies conducted to date, it has been suggested that, as
changes in the balance between excitatory and inhibitory
systems cause different effects in the development of
these epilepsies, the approaches used in their treatments
should also differ. The results of our study have once again
demonstrated this fact.
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